Table IV.
Survival outcomes by DM and metformin status in FL patients
| EFS | Univariate | Multivariate* | ||||||
|---|---|---|---|---|---|---|---|---|
| N | N events | HR | 95% CI | P value | HR | 95% CI | P value | |
| No DM, No metformin | 830 | 390 | 1.00 | reference | 0.27 | 1.00 | reference | 0.75 |
| DM, No metformin | 19 | 13 | 1.52 | 0.87–2.64 | 1.16 | 0.66–2.04 | ||
| DM, Metformin | 37 | 17 | 1.18 | 0.73–1.92 | 1.16 | 0.71–1.89 | ||
| LSS | Univariate | Multivariate* | ||||||
| N | N events | HR | 95% CI | P value | HR | 95% CI | P value | |
| No DM, No metformin | 839 | 66 | 1.00 | reference | 0.11 | 1.00 | reference | 0.56 |
| DM, No metformin | 19 | 3 | 2.13 | 0.67–6.78 | 1.01 | 0.31–3.31 | ||
| DM, Metformin | 37 | 5 | 2.25 | 0.91–5.59 | 1.67 | 0.66–4.22 | ||
| OS | Univariate | Multivariate* | ||||||
| N | N events | HR | 95% CI | P value | HR | 95% CI | P value | |
| No DM, No metformin | 839 | 140 | 1.00 | reference | <0.01 | 1.00 | reference | 0.03 |
| DM, No metformin | 19 | 7 | 2.43 | 1.14–5.20 | 1.53 | 0.70–3.32 | ||
| DM, Metformin | 37 | 12 | 2.67 | 1.48–4.81 | 2.17 | 1.19–3.95 | ||
*
Adjusted for sex, age (continuous), Follicular Lymphoma International Prognostic Index (continuous), initial management (observation vs treatment), and body mass index (categorical).
CI: confidence interval; DM: type 2 diabetes mellitus; EFS: event-free survival; FL: follicular lymphoma; HR: hazard ratio; LSS: lymphoma-specific survival; OS: overall survival.